This hypertrophy method was one of the late Charles Poliquin’s favourite muscle-building techniques and for good reason ...
New research proves the benefits of strength training for running economy – so here’s how to make the most of your ...
Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...
“The last thing a presbyopic patient wants is to abandon their reading glasses and walk around with cosmetically red eyes,” Donnenfeld noted. “In BRIO-II, the rate of reported adverse events of ocular ...
The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics. Yuvezzi ...
The burden of presbyopia and reading glasses drives patients to look for solutions.“There is a clear and growing patient demand for noninvasive, reversible options to manage presbyopia,” Behnaz ...
The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...
The FDA has approved the first dual-agent eye drop to treat presbyopia, a condition that causes gradual loss of near vision in adults.
A start-up claims dream communication is possible, but scientists say sleeping brains interaction remains unproven and speculative.
Parkinson's disease is degenerative neurological disorder that primarily affects movement due to damage to dopamine-producing nerve cells ...
Tenpoint Therapeutics’ Yuvezzi gets US FDA nod; the first and only combo eye drop approved to treat presbyopia: London Saturday, January 31, 2026, 14:00 Hrs [IST] Tenpoint Thera ...
By James Tuke, CEO, AI Futures Forum. It is late January 2026. For the past two years, the legal sector has been in a race to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results